Skip to main content
SpringerLink
Log in
Book cover

Therapiekonzepte Onkologie pp 155–169Cite as

Myeloproliferative Syndrome

  • Chapter

  • 54 Accesses

Zusammenfassung

Zu den myeloproliferativen Syndromen (MPS) zählen:

  • die chronische myeloische Leukämie (CML),

  • die Polycythaemia rubra vera (PCV),

  • die essentielle oder idiopathische Thrombocythaemie (ET)

  • die idiopathische Myelofibrose (IM).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Fonatsch C, Gradl G (1988) Cytogenetic findings in myeloproliferative disorders. In: Huhn D, Hellriegel KP, Niederle N (eds): Chronic myelocytic leukemia and interferon: pathophysiological, clinical, and therapeutical aspects. Springer-Verlag, Berlin Heidelberg New York London Paris Tokyo, 1–18

    Chapter  Google Scholar 

  2. Tartaglia ED, Goldberg JD, Berg PD, Wasserman LR (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythaemia vera. Semin Hematol 23: 172–176

    PubMed  CAS  Google Scholar 

  3. Niederle N, Moritz T, Kloke O, Wandl U, May D, Becher R, Franz T, Opalka B, Schmidt CG (1991) Interferon alfa-2b in acute-und chronic-phase chronic myelogenous leukemia: initial response and long-term results in 54 patients. Eur J Cancer 27 (Suppl 4), S 7 — S14

    Google Scholar 

  4. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069

    Article  PubMed  CAS  Google Scholar 

  5. Thaler J, Kühr T, Gastl G, Huber H, Duba C, Kemmler G, Gattringer C, Fluckinger T, Niederwieser D, Seewann H, Abbrederis K, Lang A, Gadner H, Fereberger W, Schiller I, Hausmaninger H, Weitgasser R, Michlmayr G, Fridrik M, Huber C (1991) Rekombinantes Interferon a-2c bei Ph-positiver chronischer myeloischer Leukämie. Dtsch med Wschr 116: 721–728

    Article  PubMed  CAS  Google Scholar 

  6. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alpha2-b as therapy for Ph’-positive chronic myelogenous leukemia. A study of 82 patients treated with intermittent or daily administration. Blood 72: 642–647

    PubMed  CAS  Google Scholar 

  7. Freund M, v. Wussow P, Diedrich H, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoda H (1989) Recombinant human interferron alpha 2-b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72: 350–356

    Article  PubMed  CAS  Google Scholar 

  8. Niederle N, Kloke O, Wandl UB, Becher R, Moritz Th, Opalka B (1993) Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymph 9: 111–119

    Article  CAS  Google Scholar 

  9. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820–825

    Article  Google Scholar 

  10. Kantarjian M, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82: 691–703

    PubMed  CAS  Google Scholar 

  11. Kantarijan HM, Keating MJ, Estey EH, O’Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M (1992) Treatment of advanced stages of Philadelphia chromosome-positive myelogenous leukemia with interferon-a and low-dose cytarabine. J Clin Oncol 10: 772–778

    Google Scholar 

  12. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, Masaoka T, McGlave PB, Messner H, O’Reilly RJ, Reiffers J, Rimm AA, Speck B, Veum-Stone JA, Wingard JR, Zwaan FE, Bortin MM (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82: 2235–2238

    PubMed  CAS  Google Scholar 

  13. Clift RA, Appelbaum FR, Thomas ED (1993) Tratment of chronic myeloid leukemia by marrow transplantation. Blood 82: 1954–1956

    PubMed  CAS  Google Scholar 

  14. Armitage JO (1994) Bone marrow transplantation. N Engl J Med 330: 827–838

    Article  PubMed  CAS  Google Scholar 

  15. Bortin MM, Horowith MM, Gale RP (1988) Current status of bone marrow transplantation in humans. Report from the International Bone Marrow Transplant Registry. Nat Immun Cell Growth Regul 7: 334–350

    PubMed  CAS  Google Scholar 

  16. Schmitz N (1990) Allogene Knochenmarktransplantation bei chronischer myeloischer Leukämie. Ergebnisse HLA-identischer Transplantationen in der Bundesrepublik Deutschland. Dtsch med Wschr 115: 923–929

    Article  PubMed  CAS  Google Scholar 

  17. Bolin RW, Robinson WA, Sutherland J, Hamman RF (1982) Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 50: 1683–1687

    Article  PubMed  CAS  Google Scholar 

  18. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W, Löffler H, Heinze B, Beorgii A, v. Wussow P, Bartram C, Grießhammer M, Bergmann L, Essers U, Falge C, Hochhaus A, Queißer U, Sick C, Meyer P, Schmitz N, Verpoort K, Eimermacher H, Walther F, Westerhausen M, Kleeberg UR, Heilein A, Käbisch A, Barz C, Zimmermann R, Meuret G, Tichelli A, Berdel WE, Kanz L, Anger B, Tigges FJ, Schmid L, Brockhaus W, Zankowich R, Schläfer U, Weißenfels I, Mainzer K, Tobler A, Perker M, Hohnloser J, Messemer D, Thiele J, Buhr T, Ansar H, and the German CML Study Group (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 82: 398–407

    Google Scholar 

  19. Saven A, Piro LD, Lemon RH, Figueroa ML, Kosty M, Ellison DJ, Beutler E (1994) Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 73: 2953–63

    Article  PubMed  CAS  Google Scholar 

  20. Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukemia: strategies and results. Lancet 335: 1255–1258

    Article  PubMed  CAS  Google Scholar 

  21. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D (1994) Autologous transplants for chronic myelogenous leukemia: results from eight transplant groups. Lancet 343: 1486–1488

    Article  PubMed  CAS  Google Scholar 

  22. Kolb HJ, Mittermüller J, Clemm CH, Holler E, Ledderose G, Brehn G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462–2465

    PubMed  CAS  Google Scholar 

  23. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowith MM, Flomenberg N (1993) Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82: 2310–2318

    PubMed  CAS  Google Scholar 

  24. Hellriegel KP (1981) Therapie der Blastenkrise der chronischen myeloischen Leukämie. Ergebnisse einer Phase II-Studie mit Vindesin. Folia Haematol (Leipzig) 108: 699–704

    CAS  Google Scholar 

  25. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta AV, Wasserman LR (1981) Increased incidence of acute leukemia in polycythaemia vera associated with chlorambucil therapy. New Engl J Med 304: 441–447

    Article  PubMed  CAS  Google Scholar 

  26. Berk PD, Goldberg JD, Silverstein MN et al. (1986) Therapeutic recommendations in polycythaemia vera based on Polycythaemia Vera Study Group protocols. Sem Hematol 23: 132–143

    CAS  Google Scholar 

  27. Ellis JT, Peterson P, Geller SA, Rappaport H (1986) Studies of the bone marrow in polycythaemia vera and the evolution of myelofibrosis and second hematologic malignancies. Sem Hematol 23: 144–145

    CAS  Google Scholar 

  28. Sacchi S, Leoni P, Liberati M, Riccardi A, Tabilio A, Tartoni P, Messora C, Vecchi A, Bensi L, Rupoli S, Ucci G, Falzetti F, Grignani F, Martelli MF (1994) A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol 68: 247–250

    Article  PubMed  CAS  Google Scholar 

  29. Grieshammer M, Seifried E, Heimpel H (1993) Essentielle Thrombozythämie. Klinische Bedeutung, Diagnostik and Therapie. Dtsch med Wschr 118: 1412–1417

    Article  Google Scholar 

  30. May D, Wandl UB, Niederle N (1989) Treatment of essential thrombocythaemia with interferon alpha-2b. Lancet 1: 96

    Article  PubMed  CAS  Google Scholar 

  31. Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz TH (1989) Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1: 634–637

    Article  PubMed  CAS  Google Scholar 

  32. Giles FJ, Singer CRJ, Gray AG, Yong KL, Brozovic M, Davies SC, Grant IR, Hoff-brand AV, Machin SJ, Mehta AB, Richards JDM, Thomas MJG, Venutas S, Goldstone AH (1988) Alpha-interferon therapy for essential thrombocythaemia. Lancet 2: 70–72

    Article  PubMed  CAS  Google Scholar 

  33. Murphy 5 (1983) Polycythemia vera. In: Williams WJ, Beutler E, Erslev AJ, Licht-man MA (eds): Hematology. 5rd ed, 185–196: McGraw-Hill, New York

    Google Scholar 

Download references

Authors
  1. N. Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Weidmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Niederle, N., Weidmann, B. (1995). Myeloproliferative Syndrome. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation